An Ultrasensitive and Low-Cost p24 Antigen Test for the Early Detection of HIV
用于早期检测 HIV 的超灵敏且低成本的 p24 抗原测试
基本信息
- 批准号:10482574
- 负责人:
- 金额:$ 29.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAcuteAmericasAntibodiesAntibody ResponseAntigensAreaBindingBiological AssayBiological SciencesBlood specimenCapsidCapsid ProteinsCatalysisCharacteristicsChemistryClinicComplexDataDecentralizationDetectionDeveloped CountriesDeveloping CountriesDevicesDiagnosisDiagnosticEarly DiagnosisElectrical ResistanceEpidemicEvaluationEyeGenerationsGoalsGrowthGuidelinesHIVHIV AntibodiesHIV InfectionsHIV diagnosisHIV-1Human immunodeficiency virus testHydrogen PeroxideImmune responseImmunoassayIndividualInfectionInfrastructureJointsJordanLabelLaboratoriesLeadLightLiquid substanceMagnetismMeasurementMethodsMicrofluidicsMonitorMonoclonal AntibodiesNanotechnologyNucleic Acid Amplification TestsNucleic AcidsOxygenPatient CarePatientsPersonsPhasePhysiciansPlasmaPlatinumPoint of Care TechnologyProcessRNAReagentResistanceResource-limited settingReverse Transcriptase Polymerase Chain ReactionSamplingSignal TransductionSmall Business Innovation Research GrantSyringesTechnologyTelephoneTestingTimeTrainingUnited NationsUnited States National Institutes of HealthUniversitiesValidationViralViral Load resultViremiaVirionVirusVirus DiseasesWashingtonWhole BloodWorkacute infectionantibody detectionantigen testantiretroviral therapybasecostcost effectivedesigndigitalevaluation/testinghigh risk populationinstrumentnanoparticleparticlepoint of carepoint of care testingprofessorprogramsself testingseroconversiontooltransmission process
项目摘要
PROJECT SUMMARY
The goal of this NIH SBIR Phase I proposal is to develop a low-cost and rapid point-of-care (POC) p24 test for
early detection of human immunodeficiency virus (HIV) infection. It will be appropriate for use at decentralized
settings in developed and developing countries where the limitations of infrastructure and laboratory capability
prohibit viral load-based nucleic acid testing. Our aim is to maintain the accuracy and sensitivity of traditional
lab-based diagnostics while providing a device that a minimally trained person can operate, significantly
increasing access to HIV diagnostics. The WHO guidelines recommend initiating antiretroviral therapy (ART) as
early as possible once infected, and the Joint United Nations Programme on HIV and AIDS (UNAIDS) has called
for global increases in HIV testing, treatment, and viral suppression. However, because a significant proportion
of individuals are unaware of their infection, expanding testing capabilities has a high potential to reach previously
untested high-risk populations. Current point-of-care devices that can detect HIV viremia directly are too
expensive and require some level of specialized training to operate. Also, many POC technologies that have
been approved are not sensitive enough to detect HIV during peak viremia and transmissibility in acute infection.
Existing self-testing technologies only detect the host antibody response, which arises weeks after the initial
infection. Therefore, practical and affordable POC test platforms that enable decentralized testing will be
important for the federal “Ending the HIV Epidemic: A Plan for America” initiative. To this end, AI Biosciences
proposes to develop a low-cost magnetic particle (MP) and nanoparticle based sandwich immunoassay that can
be used for the early-detection of HIV-1 p24 capsid protein with a sensitivity near that of nucleic acid amplification
approaches. This small device (~4x3x2 inches) performs MP-based p24 capture and concentration, followed by
labeling with antibody-modified platinum nanoparticles (PtNPs). The PtNPs then interact with a hydrogen
peroxide solution to create a signal that can be recorded with extremely high sensitivity using low-cost electronic
components. We aim to optimize the chemistry and assay form factor during Phase I to make a 30-min sample-
to-answer test that requires minimal training and hands-on time. We will work with Professor Chuan-Jian Zhong,
a nanotechnology and catalysis expert at Binghamton University (BU), to characterize and synthesize the
antibody modified MPs and PtNPs. AI Biosciences has also partnered with Professor Jeanne Jordan of George
Washington University (GWU)to assist with device evaluation and testing. At the end of Phase I, we will bring
our device and assay to her laboratory to perform a technology demonstration. We will train technicians to use
our device and assay for validation. They will compare the results from our immunoassay to PCR and 5th
generation immunoassays. If our approach for sensitive p24 detection is successful, we will use the same
approach for HIV antibody detection.
项目摘要
NIH SBIR第一阶段提案的目标是开发一种低成本和快速的床旁(POC)p24检测,
早期发现人类免疫缺陷病毒(HIV)感染。它将适合在分散的
在发达国家和发展中国家,基础设施和实验室能力有限,
禁止病毒载量核酸检测。我们的目标是保持传统方法的准确性和灵敏度,
基于实验室的诊断,同时提供了一个设备,一个最低限度的培训人员可以操作,显著
增加获得艾滋病毒诊断的机会。世卫组织指南建议启动抗逆转录病毒治疗(ART),
联合国艾滋病毒和艾滋病联合规划署(艾滋病规划署)呼吁,
全球艾滋病毒检测、治疗和病毒抑制的增长。然而,由于相当大的比例
的人不知道他们的感染,扩大检测能力有很大的潜力,以达到以前
未经测试的高危人群。目前可以直接检测HIV病毒血症的即时检测设备也
昂贵并且需要某种程度的专门培训来操作。此外,许多POC技术
目前已批准的新方法在病毒血症高峰期和急性感染的传播性中检测HIV的灵敏度不够。
现有的自我检测技术只能检测宿主抗体反应,这种反应是在最初的免疫反应后数周出现的。
感染因此,能够实现分散式测试的实用且经济实惠的POC测试平台将是
这对联邦“结束艾滋病流行:美国计划”倡议很重要。为此,AI Biosciences
提出开发一种低成本的基于磁性颗粒(MP)和纳米颗粒的夹心免疫测定法,
用于HIV-1 p24衣壳蛋白的早期检测,灵敏度接近核酸扩增
接近。这个小装置(~ 4x 3x 2英寸)执行基于MP的p24捕获和浓缩,然后
用抗体修饰的铂纳米颗粒(PtNPs)标记。然后PtNPs与氢原子相互作用,
过氧化氢溶液产生的信号,可以记录极高的灵敏度,使用低成本的电子
件.我们的目标是在第一阶段优化化学和测定形状因子,以制备30分钟的样品-
需要最少的培训和动手时间的测试。我们将与钟传健教授合作,
宾厄姆顿大学(BU)的纳米技术和催化专家,
抗体修饰的MP和PtNP。AI Biosciences还与乔治的Jeanne Jordan教授合作
华盛顿大学(GWU)协助进行器械评价和测试。在第一阶段结束时,我们将
我们的设备和分析到她的实验室进行技术演示。我们将培训技术人员使用
我们的设备和检测方法进行验证。他们将比较我们的免疫测定结果与PCR和第5代
代免疫测定。如果我们的敏感p24检测方法成功,我们将使用相同的方法。
检测HIV抗体的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SEASON S-S WONG其他文献
SEASON S-S WONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SEASON S-S WONG', 18)}}的其他基金
Rapid Point-of-Care Molecular Test for SARS-CoV-2 and Influenza A/B
SARS-CoV-2 和甲型/乙型流感的快速护理点分子检测
- 批准号:
10484040 - 财政年份:2022
- 资助金额:
$ 29.96万 - 项目类别:
Rapid and Low- cost POC Assay for Zika Virus Diagnosis
用于寨卡病毒诊断的快速、低成本 POC 检测
- 批准号:
9254690 - 财政年份:2017
- 资助金额:
$ 29.96万 - 项目类别:
Rapid and Ultrasensitive Direct Detection of RNA for Norovirus Gastroenteritis
快速、超灵敏直接检测诺如病毒胃肠炎 RNA
- 批准号:
8833117 - 财政年份:2015
- 资助金额:
$ 29.96万 - 项目类别:
A Portable, Self-Contained Nucleic Acid Extraction and Storage System for POC Tes
用于 POC Tes 的便携式独立核酸提取和存储系统
- 批准号:
8712053 - 财政年份:2014
- 资助金额:
$ 29.96万 - 项目类别:
A rapid, accurate, and easy-to-use diagnostic assay for STIs
一种快速、准确且易于使用的性传播感染诊断方法
- 批准号:
8713686 - 财政年份:2014
- 资助金额:
$ 29.96万 - 项目类别:
A Sensitive and Serotype-Specific Dengue Diagnostic Test for Low-Resource Setting
适用于资源匮乏环境的敏感且血清型特异性的登革热诊断测试
- 批准号:
8713439 - 财政年份:2014
- 资助金额:
$ 29.96万 - 项目类别:
A rapid, accurate, and easy-to-use diagnostic assay for STIs
一种快速、准确且易于使用的性传播感染诊断方法
- 批准号:
9347683 - 财政年份:2014
- 资助金额:
$ 29.96万 - 项目类别:
Ultrasensitive, Label-free Silicon Nanowire Biosensing Arrays
超灵敏、无标记硅纳米线生物传感阵列
- 批准号:
7670539 - 财政年份:2009
- 资助金额:
$ 29.96万 - 项目类别:
Sample Preparation and Real-Time PCR System for Non-Traditional Settings
适用于非传统设置的样品制备和实时 PCR 系统
- 批准号:
7608852 - 财政年份:2009
- 资助金额:
$ 29.96万 - 项目类别:
Rapid and Enclosed System for the Identification of Multi-Drug Resistant TB
用于识别多重耐药结核病的快速封闭系统
- 批准号:
7394908 - 财政年份:2008
- 资助金额:
$ 29.96万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 29.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 29.96万 - 项目类别:
Operating Grants